- Home
- ISRG vs AMGN Comparison
ISRG vs AMGN Comparison
Compare ISRG & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISRG
- AMGN
- Stock Information
- Founded
- ISRG 1995
- AMGN 1980
- Country
- ISRG United States
- AMGN United States
- Employees
- ISRG N/A
- AMGN N/A
- Industry
- ISRG Medical/Dental Instruments
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ISRG Health Care
- AMGN Health Care
- Exchange
- ISRG Nasdaq
- AMGN Nasdaq
- Market Cap
- ISRG 182.1B
- AMGN 156.2B
- IPO Year
- ISRG 2000
- AMGN N/A
- Fundamental
- Price
- ISRG $536.84
- AMGN $268.92
- Analyst Decision
- ISRG Strong Buy
- AMGN Buy
- Analyst Count
- ISRG 18
- AMGN 19
- Target Price
- ISRG $590.59
- AMGN $324.37
- AVG Volume (30 Days)
- ISRG 2.0M
- AMGN 2.8M
- Earning Date
- ISRG 04-22-2025
- AMGN 05-01-2025
- Dividend Yield
- ISRG N/A
- AMGN 3.50%
- EPS Growth
- ISRG 23.31
- AMGN 56.16
- EPS
- ISRG 6.83
- AMGN 10.94
- Revenue
- ISRG $8,714,900,000.00
- AMGN $34,126,000,000.00
- Revenue This Year
- ISRG $17.66
- AMGN $7.19
- Revenue Next Year
- ISRG $15.45
- AMGN $2.37
- P/E Ratio
- ISRG $78.79
- AMGN $24.86
- Revenue Growth
- ISRG 19.08
- AMGN 15.56
- 52 Week Low
- ISRG $379.67
- AMGN $253.30
- 52 Week High
- ISRG $616.00
- AMGN $346.85
- Technical
- Relative Strength Index (RSI)
- ISRG 62.11
- AMGN 38.46
- Support Level
- ISRG $522.95
- AMGN $266.02
- Resistance Level
- ISRG $546.56
- AMGN $291.61
- Average True Range (ATR)
- ISRG 13.40
- AMGN 7.29
- MACD
- ISRG 4.73
- AMGN -0.36
- Stochastic Oscillator
- ISRG 88.01
- AMGN 23.23
About ISRG Intuitive Surgical Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 9,500 da Vinci systems in hospitals worldwide, with more than 5,500 installations in the US and a growing number in emerging markets.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.